Andreas C. Chai

Andreas C. Chai

Auto-generated profile, based on publicly available information

Andreas C. Chai

Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
FCFrancesco Chemello
Francesco Chemello
ACA. C. Chai
A. C. Chai
HLH. Li
H. Li
CRC. Rodriguez-Caycedo
C. Rodriguez-Caycedo
ESE. Sanchez-Ortiz
E. Sanchez-Ortiz
EOE. N. Olson
E. N. Olson
Base and prime genome editing correct Duchenne muscular dystrophy mutations to restore dystrophin in mice and human cells.

16 February 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ACAndreas C. Chai
Andreas C. Chai
MCMiao Cui
Miao Cui
FCFrancesco Chemello
Francesco Chemello
HLHui Li
Hui Li
KCKenian Chen
Kenian Chen
EOEric N. Olson
Eric N. Olson

6 May 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
CYChristopher L. Yankaskas
Christopher L. Yankaskas
KTKeyata N. Thompson
Keyata N. Thompson
CPColin D. Paul
Colin D. Paul
MVMichele I. Vitolo
Michele I. Vitolo
PANAGIOTIS MISTRIOTISPANAGIOTIS MISTRIOTIS
PANAGIOTIS MISTRIOTIS
KKKonstantinos Konstantopoulos
Konstantinos Konstantopoulos

22 February 2016 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CPColin D. Paul
Colin D. Paul
DSDaniel J. Shea
Daniel J. Shea
MMMegan R. Mahoney
Megan R. Mahoney
ACAndreas Chai
Andreas Chai
VLVictoria Laney
Victoria Laney
KKKonstantinos Konstantopoulos
Konstantinos Konstantopoulos
The peritumoral physical microenvironment consists of complex topographies that influence cell migration. Cell decision making, upon encountering anisotropic, physiologically relevant physical cues, has yet to be elucidated. By integrating microfabrication with cell and molecular biology techniques, we provide a quantitative and mechanistic analysis of cell decision making in a variety of well‐defined physical microenvironments. We used MDA‐MB‐231 breast carcinoma and HT1080 fibrosarcoma as cell models. Cell decision making after lateral confinement in 2‐dimensional microcontact printed lines is governed by branch width at bifurcations. Cells confined in narrow feeder microchannels prefer to enter wider branches at bifurcations. In contrast, in feeder channels that are wider than the cell body, cells elongate along one side wall of the channel and are guided by contact with the wall to the contiguous branch channel independent of its width. Knockdown of β1‐integrins or inhibition of cellular contractility suppresses contact guidance. Concurrent, but not individual, knockdown of nonmuscle myosin iso‐forms IIA and IIB also decreases contact guidance, which suggests the existence of a compensatory mechanism between myosin IIA and myosin IIB. Conversely, knockdown or inhibition of cell division control protein 42 homolog promotes contact guidance‐mediated decision making. Taken together, the dimensionality, length scales of the physical microenvironment, and intrinsic cell signaling regulate cell decision making at intersections.—Paul, C. D., Shea, D. J., Mahoney, M. R., Chai, A., Laney, V., Hung, W.‐C., Konstantopoulos, K. Interplay of the physical microenvironment, contact guidance, and intracellular signaling in cell decision making. FASEB J. 30, 2161–2170 (2016). www.fasebj.org

19 April 2023 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
ACAndreas C. Chai
Andreas C. Chai
FCFrancesco Chemello
Francesco Chemello
HLHui Li
Hui Li
TNTakahiko Nishiyama
Takahiko Nishiyama
KCKenian Chen
Kenian Chen
EOEric N. Olson
Eric N. Olson
Duchenne muscular dystrophy (DMD) is a fatal X-linked recessive disease of progressive muscle weakness and wasting caused by the absence of dystrophin protein. Current gene therapy approaches using antisense oligonucleotides require lifelong dosing and have limited efficacy in restoring dystrophin production. A gene editing approach could permanently correct the genome and restore dystrophin protein expression. Here, we describe single-swap editing, in which an adenine base editor edits a single base pair at a splice donor site or splice acceptor site to enable exon skipping or reframing. In human induced pluripotent stem cell-derived cardiomyocytes, we demonstrate that single-swap editing can enable beneficial exon skipping or reframing for the three most therapeutically relevant exons—DMD exons 45, 51, and 53—which could be beneficial for 30% of all DMD patients. Furthermore, an adeno-associated virus delivery method for base editing components can efficiently restore dystrophin production locally and systemically in skeletal and cardiac muscles of a DMD mouse model containing a deletion of Dmd exon 44. Our studies demonstrate single-swap editing as a potential gene editing therapy for common DMD mutations.

3 September 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
AAAyhan Atmanli
Ayhan Atmanli
ACAndreas C. Chai
Andreas C. Chai
MCMiao Cui
Miao Cui
ZWZhaoning Wang
Zhaoning Wang
TNTakahiko Nishiyama
Takahiko Nishiyama
EOEric N. Olson
Eric N. Olson
Rationale: Absence of dystrophin in Duchenne muscular dystrophy (DMD) results in the degeneration of skeletal and cardiac muscles. Owing to advances in respiratory management of patients with DMD, cardiomyopathy has become a significant aspect of the disease. While CRISPR/Cas9 genome editing technology holds great potential as a novel therapeutic avenue for DMD, little is known about the potential of DMD correction using CRISPR/Cas9 technology to mitigate cardiac abnormalities in DMD. Objective: To define the effects of CRISPR/Cas9 genome editing on structural, functional, and transcriptional abnormalities in DMD-associated cardiac disease. Methods and Results: We generated induced pluripotent stem cells from a patient with a deletion of exon 44 of the DMD gene (ΔEx44) and his healthy brother. We targeted exon 45 of the DMD gene by CRISPR/Cas9 genome editing to generate corrected DMD induced pluripotent stem cell lines, wherein the DMD open reading frame was restored via reframing or exon skipping. While DMD cardiomyocytes demonstrated morphological, structural, and functional deficits compared with control cardiomyocytes, cardiomyocytes from both corrected DMD lines were similar to control cardiomyocytes. Bulk RNA-sequencing of DMD cardiomyocytes showed transcriptional dysregulation consistent with dilated cardiomyopathy, which was mitigated in corrected DMD cardiomyocytes. We then corrected dysfunctional DMD cardiomyocytes by adenoviral delivery of Cas9/gRNA and showed that correction of DMD cardiomyocytes postdifferentiation reduces their arrhythmogenic potential. Single-nucleus RNA-sequencing of hearts of DMD mice showed transcriptional dysregulation in cardiomyocytes and fibroblasts, which in corrected mice was reduced to similar levels as wild-type mice. Conclusions: We show that CRISPR/Cas9-mediated correction of DMD ΔEx44 mitigates structural, functional, and transcriptional abnormalities consistent with dilated cardiomyopathy irrespective of how the protein reading frame is restored. We show that these effects extend to postnatal editing in induced pluripotent stem cell-derived cardiomyocytes and mice. These findings provide key insights into the utility of genome editing as a novel therapeutic for DMD-associated cardiomyopathy.